2.12
6.00%
0.12
Handel nachbörslich:
2.09
-0.03
-1.42%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.00
Offen:
$2
24-Stunden-Volumen:
5.34M
Relative Volume:
1.53
Marktkapitalisierung:
$398.81M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-0.7518
EPS:
-2.82
Netto-Cashflow:
$-135.49M
1W Leistung:
+1.92%
1M Leistung:
-1.85%
6M Leistung:
+1.92%
1J Leistung:
+105.83%
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2021-05-05 | Herabstufung | Stifel | Buy → Hold |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
2019-01-07 | Bestätigt | Needham | Strong Buy |
2018-12-13 | Eingeleitet | Goldman | Sell |
2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
2018-10-16 | Eingeleitet | BTIG Research | Buy |
2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Vanguard Group Inc's Strategic Acquisition in Esperion Therapeutics Inc - GuruFocus.com
Esperion to Participate in Upcoming Jefferies London Healthcare Conference - GlobeNewswire
Esperion Announces a Featured Presentation in the Late - GlobeNewswire
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three - The Bakersfield Californian
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions - Yahoo Finance
Esperion Therapeutics (ESPR) Set to Announce Quarterly Earnings on Thursday - MarketBeat
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy - MarketBeat
Esperion to Report Third Quarter 2024 Financial Results on November 7 - GlobeNewswire
ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Nexletol From Esperion - Pharmacy Times
Esperion Therapeutics' chief commercial officer sells shares worth $226 - Investing.com
Esperion Therapeutics' chief commercial officer sells shares worth $226 By Investing.com - Investing.com UK
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance
Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by Zacks Research - MarketBeat
Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com - MarketBeat
Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Cut by Analyst - MarketBeat
Esperion shares reiterate Buy rating on trial data By Investing.com - Investing.com South Africa
Esperion shares reiterate Buy rating on trial data - Investing.com India
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5? - Insider Monkey
Esperion reports LDL-C reduction success in MILOS study By Investing.com - Investing.com South Africa
Esperion reports LDL-C reduction success in MILOS study - Investing.com
Esperion Therapeutics' (ESPR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid - The Manila Times
Esperion EU Partner Reports Final Real-World Results from - GlobeNewswire
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Large Decline in Short Interest - MarketBeat
Marshall Wace LLP Raises Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
7 Best NASDAQ Stocks Under $5 - Insider Monkey
Esperion Therapeutics (NASDAQ:ESPR) Lowered to Hold at StockNews.com - MarketBeat
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World
Taking a Closer Look At Esperion Therapeutics Inc. (ESPR) Following Its Recent Trade - Knox Daily
ESH Acquisition Corp. (NASDAQ:ESHA) Shares Bought by Berkley W R Corp - Defense World
What's Going On With Seelos Therapeutics Stock Tuesday? - Benzinga
Great Point Partners LLC Sells 2,208,406 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
ESAB Co. (NYSE:ESAB) Stock Position Cut by Front Street Capital Management Inc. - Defense World
Seelos Therapeutics surges on deal with U.S. Army to develop PTSD drug - XM
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Sold by Great Point Partners LLC - MarketBeat
New Pill Cuts Cholesterol and Heart Attacks - Greek Reporter
What to expect from Esperion Therapeutics Inc.’s (ESPR) current quarter earnings? - US Post News
Atopic dermatitis: New drug significantly improves symptoms - Medical News Today
How does ESAB Corp (ESAB) change from a tortoise to a hare? - SETE News
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Raised by XTX Topco Ltd - Defense World
XTX Topco Ltd Has $810,000 Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Espey Mfg. & Electronics (NYSEAMERICAN:ESP) Receives New Coverage from Analysts at StockNews.com - Defense World
Inspire Investing LLC Invests $758,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
ESAB Co. (NYSE:ESAB) Shares Sold by Granite Investment Partners LLC - Defense World
Bank of New York Mellon Corp Acquires 555,382 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
18,727 Shares in ESAB Co. (NYSE:ESAB) Bought by Seven Eight Capital LP - Defense World
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):